US-based biopharmaceutical company Celladon closed a $43 equity round on Wednesday led by Pfizer Ventures, the corporate venturing fund for pharmaceutical corporation Pfizer.

Two other corporate venturing funds for pharma companies – Novartis Venture Funds, and Johnson & Johnson Development Corporation – also participated in the round, as did life science venture funds Hambrecht & Quist Healthcare/Life Sciences Investors and Lundbeckfond Ventures, and venture capital firms Venrock, Enterprise Partners and GBS Venture Partners.

The cash will be used to advance…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?